Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
The Journal of Headache and Pain
|
April 28, 2022
Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
The Journal of Headache and Pain
|
April 10, 2022
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
Cephalalgia : an International Journal of Headache
|
October 9, 2024
Insights from triggers and prodromal symptoms on how migraine attacks start: The threshold hypothesis
Gabriele Sebastianelli, Arife Çimen Atalar, Ilaria Cetta, et al.
The Journal of Headache and Pain
|
March 3, 2024
The impact of primary headaches on disability outcomes: a literature review and meta-analysis to inform future iterations of the Global Burden of Disease study
Marta Waliszewska-Prosół, Danilo Antonio Montisano, Mariola Antolak, et al.
Journal of Neurology
|
August 7, 2023
The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN)
Massimo Filippi, Roberta Messina, Marta Bartezaghi, et al.
Journal of Neurology
|
July 19, 2023
Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study
Fabrizio Vernieri, Nicoletta Brunelli, Simona Guerzoni, et al.
Journal of Neurology
|
January 17, 2024
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Journal of Neurology
|
April 2, 2024
Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
The Journal of Headache and Pain
|
April 28, 2022
Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
The Journal of Headache and Pain
|
April 10, 2022
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
Cephalalgia : an International Journal of Headache
|
October 9, 2024
Insights from triggers and prodromal symptoms on how migraine attacks start: The threshold hypothesis
Gabriele Sebastianelli, Arife Çimen Atalar, Ilaria Cetta, et al.
The Journal of Headache and Pain
|
March 3, 2024
The impact of primary headaches on disability outcomes: a literature review and meta-analysis to inform future iterations of the Global Burden of Disease study
Marta Waliszewska-Prosół, Danilo Antonio Montisano, Mariola Antolak, et al.
Journal of Neurology
|
August 7, 2023
The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN)
Massimo Filippi, Roberta Messina, Marta Bartezaghi, et al.
Journal of Neurology
|
July 19, 2023
Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study
Fabrizio Vernieri, Nicoletta Brunelli, Simona Guerzoni, et al.
Journal of Neurology
|
January 17, 2024
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Journal of Neurology
|
April 2, 2024
Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Page
of 2